GAIA-102 for advanced stomach or pancreatic cancer with ascites
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug, GAIA-102, given directly into the abdomen to treat advanced stomach or pancreatic cancer that has spread to the belly lining and causes fluid buildup (malignant ascites). The goal is to see if it can slow the cancer or improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or pancreatic cancer that cannot be removed by surgery and has spread to the belly lining (causing fluid buildup or visible spread on scans).
- For stomach cancer: You have tried at least 2–3 previous chemotherapy regimens (depending on the phase), and your cancer has not responded or you could not tolerate them. For pancreatic cancer: You have tried at least 1–2 previous chemotherapy regimens, with similar lack of response or intolerance.
- If you have stomach cancer, it must be HER2-negative (a specific test result), and you must not have had a serious allergic reaction to certain drugs (like pembrolizumab).
- You are 20 years or older and are generally well enough to be up and about (performance status 0–1 for phase II, or 0–2 for phase I).
- Your blood tests show adequate liver, kidney, and bone marrow function (e.g., normal blood cell counts, liver enzymes within limits).
- You do not have untreated brain metastases, active autoimmune disease, or serious heart/lung conditions, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
This Phase 1 study tests GAIA-102 in children and young adults whose cancer has returned or not responded to standard treatments. It aims to see if the treatment is safe and whether it may shrink tumors in certain pediatric solid cancers.
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.